Here we report that an engineered microbial cytochrome P450 BM-3 (CYP102A1 subfamily) efficiently catalyzes the α-hydroxylation of phenylacetic acid esters. This P450 BM-3 variant also produces the authentic human metabolite of buspirone, R-6-hydroxybuspirone, with 99.5% ee.
No cytochrome P450 that accepts 2-arylacetic acids as substrate is reported in the literature. α-Hydroxylation of carboxylic acids has only been reported for P450 BSβ and SPα, both of which are active only on long-chain fatty acids (e.g. myristic acid) and only as peroxygenases. 18 We were therefore interested in whether BM-3 variants could hydroxylate small aromatic carboxylic acids.
Observations in our laboratory suggested that small charged molecules such as carboxylic acids are unlikely to be accepted by the hydrophobic active site of BM-3. Recent studies have shown that protecting groups can strongly influence P450 activity. 8, 19 Therefore, using differentsized ester groups to mask the acid we investigated whether the chain length of the substrate influences binding and specificity of hydroxylation.
BM-3 shows low activity with moderate enantioselectivity on 2-phenylacetic acid esters (Table  1 ). For example, the methyl and propyl esters of (S)-mandelic acid were obtained in 90 and 82% enantiomeric excess (ee), respectively. The low total turnover number (TTN; mol product per mol catalyst) for BM-3 likely reflects an active site evolved for the alkyl tails of fatty acids, which leads to increased uncoupling (consuming NADPH co-factor without oxidizing the substrate) for non-natural substrates.
It is known that mutations at F87 can increase BM-3 activity towards small aromatic compounds. 20 We found that the F87A mutation increased the TTN nearly 10-fold and increased regioselectivity for the α-hydroxylated product to as high as 99% on the propyl ester. The ee for this reaction depends on the size of the ester group and varies from 43 to 85% ee, with the highest value for the propyl ester. We also tested variants of BM-3 which were evolved previously for high activity on medium-chain alkanes, 9-10A and 1-12G (differing by 14 and 16 mutations, respectively, from the wildtype sequence), 11 to see if they exhibit higher TTN on substrates 1a-d. Bioconversions with 1-12G showed 5-20 fold less conversion and very low regioselectivity for the desired products in comparison to BM-3-F87A and was therefore excluded from further investigations (data not shown). Variant 9-10A, on the other hand, showed increased TTN on the propyl and butyl esters. We then constructed 9-10A with the F87A mutation and found that this 9-10A-F87A variant has the highest TTN (up to 1640) and gives propyl mandelate in 93% ee. Each 9-10A-F87A enzyme catalyzes the hydroxylation of 254±29 molecules per minute with 25% coupling to cofactor consumption.
9-10A-F87A also hydroxylates substituted substrates such as m-chloro phenylacetic acid ( Table 2 ). The ee values are comparable to those obtained for phenylacetic acid, although the highest ee was obtained for the butyl rather than the propyl ester.
The reaction can be improved with a system which regenerates the expensive NADPH cofactor in situ. 21 Use of a regeneration system involving isocitrate dehydrogenase and isocitrate increased the TTN for the production of propyl mandelate by 9-10A-F87A from 1640 to over 5800 in a 3h reaction with NADPH concentration maintained at 50 μM. Lower concentrations increased TTN; high concentrations of cofactor inhibit the wildtype enzyme 22 and possibly our variants. The ee and selectivity were unchanged. Using the regeneration system with 500 nM enzyme yielded 96% conversion of 15 ml of 1 mM propyl phenylacetate in a batch reaction after 7h.
Motivated by the high enantioselectivity and activity of this variant, we decided to test its ability to hydroxylate the α-position of the peptide group of buspirone (Buspar®, 4). Buspirone is a known substrate of human CYP3A4, 23 and both it and its human metabolite, 6-hydroxybuspirone (5), are anti-anxiety agents. 24 Bioconversion on 0.5 ml scale with 50 nM 9-10A-F87A gave 3800 TTN and 8.9% conversion of a 2 mM buspirone solution. (R)-6-hydroxybuspirone (5) was the sole product and was obtained with >99.5% ee. Interestingly, this R-enantioselectivity is the opposite of that usually observed when buspirone is converted by natural microbial cultures. 24 A 7h bioconversion with cofactor regeneration yielded up to 72% conversion. Thus the bacterial P450 variant efficiently produces an authentic human metabolite of the drug.
The F87A mutation likely carves out space in the BM-3 active site and allows a wider range of substrates to be bound with a defined orientation. By varying the chain length of the ester substrates we can improve catalyst selectivity and probe the active site. Enantioselective hydroxylation in the α-position of carboxylic acid or peptide derivatives represents a novel reaction type by P450 BM-3 and opens up a new biocatalytic route to (S)-mandelic acid derivatives and (R)-6-hydroxybuspirone.
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